{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:37:49Z","timestamp":1784043469265,"version":"3.55.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","sleep.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine Clinics"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jsmc.2020.02.002","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T16:28:11Z","timestamp":1588696091000},"page":"133-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Prescription Drugs Used in Insomnia"],"prefix":"10.1016","volume":"15","author":[{"given":"Sylvie","family":"Dujardin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelique","family":"Pijpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Pevernagie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsmc.2020.02.002_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.smrv.2017.02.001","article-title":"Cognitive and behavioral therapies in the treatment of insomnia: a meta-analysis","volume":"38","author":"van Straten","year":"2018","journal-title":"Sleep Med Rev"},{"issue":"2","key":"10.1016\/j.jsmc.2020.02.002_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5664\/jcsm.6470","article-title":"Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline","volume":"13","author":"Sateia","year":"2017","journal-title":"J\u00a0Clin Sleep Med"},{"issue":"6","key":"10.1016\/j.jsmc.2020.02.002_bib3","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/jsr.12594","article-title":"European guideline for the diagnosis and treatment of insomnia","volume":"26","author":"Riemann","year":"2017","journal-title":"J\u00a0Sleep Res"},{"issue":"19","key":"10.1016\/j.jsmc.2020.02.002_bib4","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.2009.682","article-title":"Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial","volume":"301","author":"Morin","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jsmc.2020.02.002_bib5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1471-244X-8-80","article-title":"Discontinuation of hypnotics during cognitive behavioural therapy for insomnia","volume":"8","author":"Zavesicka","year":"2008","journal-title":"BMC Psychiatry"},{"issue":"6","key":"10.1016\/j.jsmc.2020.02.002_bib6","first-page":"925","article-title":"Effect of placebo conditions on polysomnographic parameters in primary insomnia: a meta-analysis","volume":"38","author":"Winkler","year":"2015","journal-title":"Sleep"},{"key":"10.1016\/j.jsmc.2020.02.002_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.smrv.2017.03.006","article-title":"A\u00a0systematic review and meta-analysis of placebo versus no treatment for insomnia symptoms","volume":"38","author":"Yeung","year":"2018","journal-title":"Sleep Med Rev"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.002_bib8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.smrv.2008.08.001","article-title":"A\u00a0compendium of placebo-controlled trials of the risks\/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice","volume":"13","author":"Krystal","year":"2009","journal-title":"Sleep Med Rev"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.002_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jsmc.2013.06.002","article-title":"Optimizing the pharmacologic treatment of insomnia: current status and future horizons","volume":"8","author":"Minkel","year":"2013","journal-title":"Sleep Med Clin"},{"issue":"6","key":"10.1016\/j.jsmc.2020.02.002_bib10","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nrd2464","article-title":"Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time","volume":"7","author":"Wafford","year":"2008","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.jsmc.2020.02.002_bib11","first-page":"S19","article-title":"Sleep circuitry and the hypnotic mechanism of GABAA drugs","volume":"2","author":"Lu","year":"2006","journal-title":"J\u00a0Clin Sleep Med"},{"issue":"7063","key":"10.1016\/j.jsmc.2020.02.002_bib12","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/nature04284","article-title":"Hypothalamic regulation of sleep and circadian rhythms","volume":"437","author":"Saper","year":"2005","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.002_bib13","first-page":"154","article-title":"Effects of triazolam microinjections into the peri-fornicular region on sleep in rats","volume":"5","author":"Mendelson","year":"2003","journal-title":"Sleep Hypnosis"},{"key":"10.1016\/j.jsmc.2020.02.002_bib14","series-title":"Molecular neuropharmacology: a foundation for clinical neuroscience","author":"Nestler","year":"2015"},{"issue":"6755","key":"10.1016\/j.jsmc.2020.02.002_bib15","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/44579","article-title":"Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes","volume":"401","author":"Rudolph","year":"1999","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jsmc.2020.02.002_bib16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/JCP.0b013e31816a9e4f","article-title":"Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial","volume":"28","author":"Glass","year":"2008","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.002_bib17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000092892","article-title":"Comparison of sleep condition and sleep-related psychological activity after cognitive-behavior and pharmacological therapy for chronic insomnia","volume":"75","author":"Wu","year":"2006","journal-title":"Psychother Psychosom"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.002_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s002130000661","article-title":"Treatment regimen and hypnotic self-administration","volume":"155","author":"Roehrs","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"issue":"6319","key":"10.1016\/j.jsmc.2020.02.002_bib19","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/bmj.284.6319.860","article-title":"Benzodiazepine hypnotics remain effective for 24 weeks","volume":"284","author":"Oswald","year":"1982","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"1\u20132","key":"10.1016\/j.jsmc.2020.02.002_bib20","first-page":"1","article-title":"The problems of long-term treatment with benzodiazepines and related substances","volume":"112","author":"Janhsen","year":"2015","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.002_bib21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1532-5415.2012.03923.x","article-title":"American Geriatrics Society updated beers criteria for potentially inappropriate medication use in older adults: the American Geriatrics Society 2012 beers criteria update expert panel","volume":"60","author":"Campanelli","year":"2012","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"2","key":"10.1016\/j.jsmc.2020.02.002_bib22","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5664\/jcsm.27772","article-title":"Comorbid insomnia and obstructive sleep apnea: challenges for clinical practice and research","volume":"6","author":"Luyster","year":"2010","journal-title":"J\u00a0Clin Sleep Med"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.002_bib23","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jsmc.2010.08.002","article-title":"Drug-related sleep stage changes: functional significance and clinical relevance","volume":"5","author":"Roehrs","year":"2010","journal-title":"Sleep Med Clin"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.002_bib24","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/sleep\/26.3.313","article-title":"Sleep EEG power spectra, insomnia, and chronic use of benzodiazepines","volume":"26","author":"Bastien","year":"2003","journal-title":"Sleep"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.002_bib25","first-page":"189","article-title":"Effect of benzodiazepine hypnotics on all-night sleep EEG spectra","volume":"4","author":"Borbely","year":"1985","journal-title":"Hum Neurobiol"},{"key":"10.1016\/j.jsmc.2020.02.002_bib26","series-title":"Principles and practice of sleep medicine","first-page":"425","article-title":"Hypnotic medications: mechanisms of action and pharmacologic effects","author":"Kilduff","year":"2017"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.002_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5664\/jcsm.3354","article-title":"Polysomnographic findings in a cohort of chronic insomnia patients with benzodiazepine abuse","volume":"10","author":"Mazza","year":"2014","journal-title":"J\u00a0Clin Sleep Med"},{"key":"10.1016\/j.jsmc.2020.02.002_bib28","series-title":"Prise en charge de l\u2019insomnie: guide pratique","author":"Royant-Parola","year":"2017"},{"key":"10.1016\/j.jsmc.2020.02.002_bib29","series-title":"Stahl\u2019s essential psychopharmacology: neuroscientific basis and practical applications","author":"Stahl","year":"2013"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.002_bib30","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2165\/00003495-200059040-00014","article-title":"Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in\u00a0the treatment of insomnia","volume":"59","author":"Holm","year":"2000","journal-title":"Drugs"},{"issue":"D1","key":"10.1016\/j.jsmc.2020.02.002_bib31","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.002_bib32","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00003088-200443040-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone","volume":"43","author":"Drover","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.002_bib33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5664\/jcsm.27185","article-title":"A\u00a0polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia","volume":"4","author":"Erman","year":"2008","journal-title":"J\u00a0Clin Sleep Med"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.002_bib34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1389-9457(99)00006-4","article-title":"A\u00a0five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia","volume":"1","author":"Walsh","year":"2000","journal-title":"Sleep Med"},{"issue":"2","key":"10.1016\/j.jsmc.2020.02.002_bib35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13181-013-0294-y","article-title":"In the Zzz zone: the effects of Z-drugs on human performance and driving","volume":"9","author":"Gunja","year":"2013","journal-title":"J\u00a0Med Toxicol"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.002_bib36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsmc.2014.11.002","article-title":"Non-benzodiazepine receptor agonists for insomnia","volume":"10","author":"Becker","year":"2015","journal-title":"Sleep Med Clin"},{"issue":"7","key":"10.1016\/j.jsmc.2020.02.002_bib37","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/sleep\/26.7.793","article-title":"Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia","volume":"26","author":"Krystal","year":"2003","journal-title":"Sleep"},{"issue":"5","key":"10.1016\/j.jsmc.2020.02.002_bib38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00002512-199303050-00006","article-title":"Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic","volume":"3","author":"Wadworth","year":"1993","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.002_bib39","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00002826-200001000-00011","article-title":"Central nervous system side effects associated with zolpidem treatment","volume":"23","author":"Toner","year":"2000","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.002_bib40","first-page":"143","article-title":"Zaleplon-induced anemsic somnambulism with eating behaviors under once dose","volume":"23","author":"Chen","year":"2014","journal-title":"Acta Neurol Taiwan"},{"issue":"2","key":"10.1016\/j.jsmc.2020.02.002_bib41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/ageing\/afx167","article-title":"Z-drugs and risk for falls and fractures in older adults: a systematic review and meta-analysis","volume":"47","author":"Treves","year":"2018","journal-title":"Age Ageing"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.002_bib42","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/clpt.2011.3","article-title":"Benzodiazepine-like hypnotics and the associated risk of road traffic\u00a0accidents","volume":"89","author":"Orriols","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.002_bib43","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/j.1365-2125.2012.04410.x","article-title":"Psychotropic drugs and risk of motor vehicle accidents: a population-based case-control study","volume":"75","author":"Chang","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.jsmc.2020.02.002_bib44","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/nn.3810","article-title":"Motivational activation: a unifying hypothesis of orexin\/hypocretin function","volume":"17","author":"Mahler","year":"2014","journal-title":"Nat Neurosci"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.002_bib45","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s11910-010-0101-y","article-title":"Hypocretins in the control of sleep and wakefulness","volume":"10","author":"Bonnavion","year":"2010","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.002_bib46","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.002_bib47","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Database issue","key":"10.1016\/j.jsmc.2020.02.002_bib48","doi-asserted-by":"crossref","first-page":"D1091","DOI":"10.1093\/nar\/gkt1068","article-title":"DrugBank 4.0: shedding new light on drug metabolism","volume":"42","author":"Law","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1016\/j.jsmc.2020.02.002_bib49","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials","volume":"79","author":"Herring","year":"2016","journal-title":"Biol Psychiatry"},{"issue":"23","key":"10.1016\/j.jsmc.2020.02.002_bib50","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","article-title":"Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant","volume":"79","author":"Herring","year":"2012","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jsmc.2020.02.002_bib51","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.jsmc.2020.02.002_bib52","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.5664\/jcsm.6116","article-title":"Suvorexant in patients with insomnia: pooled analyses of three-month data from phase-3 randomized controlled clinical trials","volume":"12","author":"Herring","year":"2016","journal-title":"J\u00a0Clin Sleep Med"},{"key":"10.1016\/j.jsmc.2020.02.002_bib53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.sleep.2015.10.007","article-title":"Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data","volume":"19","author":"Snyder","year":"2016","journal-title":"Sleep Med"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.002_bib54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5664\/jcsm.5382","article-title":"Effects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apnea","volume":"12","author":"Sun","year":"2016","journal-title":"J\u00a0Clin Sleep Med"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.002_bib55","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.rmed.2014.12.010","article-title":"Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease","volume":"109","author":"Sun","year":"2015","journal-title":"Respir Med"},{"issue":"10","key":"10.1016\/j.jsmc.2020.02.002_bib56","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/jcph.523","article-title":"Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects","volume":"55","author":"Uemura","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.jsmc.2020.02.002_bib57","doi-asserted-by":"crossref","first-page":"759","DOI":"10.5664\/jcsm.6600","article-title":"Suvorexant-induced dream enactment behavior in parkinson disease: a case report","volume":"13","author":"Tabata","year":"2017","journal-title":"J\u00a0Clin Sleep Med"},{"key":"10.1016\/j.jsmc.2020.02.002_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-222037","article-title":"Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts","author":"Petrous","year":"2017","journal-title":"BMJ Case Rep"},{"issue":"10","key":"10.1016\/j.jsmc.2020.02.002_bib59","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/14728222.2016.1179284","article-title":"Melatonin receptors as therapeutic targets in the suprachiasmatic nucleus","volume":"20","author":"Pevet","year":"2016","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.002_bib60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0896-6273(00)80350-5","article-title":"Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock","volume":"19","author":"Liu","year":"1997","journal-title":"Neuron"},{"key":"10.1016\/j.jsmc.2020.02.002_bib61","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev-pharmtox-010814-124742","article-title":"MT1 and MT2 melatonin receptors: a therapeutic perspective","volume":"56","author":"Liu","year":"2016","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.002_bib62","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.pneurobio.2008.04.001","article-title":"Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways","volume":"85","author":"Pandi-Perumal","year":"2008","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.jsmc.2020.02.002_bib63","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40360-016-0052-2","article-title":"Pharmacokinetics of oral and intravenous melatonin in healthy volunteers","volume":"17","author":"Andersen","year":"2016","journal-title":"BMC Pharmacol Toxicol"},{"issue":"8","key":"10.1016\/j.jsmc.2020.02.002_bib64","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00228-015-1873-4","article-title":"Clinical pharmacokinetics of melatonin: a systematic review","volume":"71","author":"Harpsoe","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.002_bib65","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.smrv.2007.12.005","article-title":"Efficacy and clinical safety of ramelteon: an evidence-based review","volume":"12","author":"Sateia","year":"2008","journal-title":"Sleep Med Rev"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.002_bib66","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/0748730415616678","article-title":"Prospective study on salivary evening melatonin and sleep before and after pinealectomy in humans","volume":"31","author":"Slawik","year":"2016","journal-title":"J\u00a0Biol Rhythms"},{"key":"10.1016\/j.jsmc.2020.02.002_bib67","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.smrv.2016.06.005","article-title":"Evidence for the efficacy of melatonin in the treatment of primary\u00a0adult sleep disorders","volume":"34","author":"Auld","year":"2017","journal-title":"Sleep Med Rev"},{"issue":"5","key":"10.1016\/j.jsmc.2020.02.002_bib68","doi-asserted-by":"crossref","first-page":"e63773","DOI":"10.1371\/journal.pone.0063773","article-title":"Meta-analysis: melatonin for the treatment of primary sleep disorders","volume":"8","author":"Ferracioli-Oda","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jsmc.2020.02.002_bib69","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/sleep\/23.5.1i","article-title":"Hypnotic activity of melatonin","volume":"23","author":"Stone","year":"2000","journal-title":"Sleep"},{"issue":"7","key":"10.1016\/j.jsmc.2020.02.002_bib70","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1177\/0269881115581963","article-title":"Randomised clinical trial of the effects of prolonged-release melatonin, temazepam and zolpidem on slow-wave activity during sleep in healthy people","volume":"29","author":"Arbon","year":"2015","journal-title":"J\u00a0Psychopharmacol"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.002_bib71","doi-asserted-by":"crossref","first-page":"351","DOI":"10.5665\/sleep\/32.3.351","article-title":"Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia","volume":"32","author":"Mayer","year":"2009","journal-title":"Sleep"},{"key":"10.1016\/j.jsmc.2020.02.002_bib72","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1741-7015-8-51","article-title":"Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety","volume":"8","author":"Wade","year":"2010","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.002_bib73","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2174\/1570159X14666161228122115","article-title":"Melatonin: pharmacology, functions and therapeutic benefits","volume":"15","author":"Tordjman","year":"2017","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.jsmc.2020.02.002_bib74","unstructured":"Available at: https:\/\/www.fda.gov\/Drugs\/DrugSafety. Accessed January 22, 2018."},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.002_bib75","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jsmc.2010.08.010","article-title":"Antidepressant and antipsychotic drugs","volume":"5","author":"Krystal","year":"2010","journal-title":"Sleep Med Clin"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.002_bib76","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/187152707779940835","article-title":"Effects of psychiatric medications on sleep and sleep disorders","volume":"6","author":"DeMartinis","year":"2007","journal-title":"CNS\u00a0Neurol Disord Drug Targets"},{"key":"10.1016\/j.jsmc.2020.02.002_bib77","series-title":"Principles and practice of sleep medicine","first-page":"432","article-title":"Clinical pharmacology of other drugs used as hypnotics","author":"Buysse","year":"2017"},{"issue":"2","key":"10.1016\/j.jsmc.2020.02.002_bib78","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.sleep.2011.09.006","article-title":"Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia","volume":"13","author":"Lankford","year":"2012","journal-title":"Sleep Med"},{"issue":"10","key":"10.1016\/j.jsmc.2020.02.002_bib79","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.4088\/JCP.v69n1005","article-title":"Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study","volume":"69","author":"Scharf","year":"2008","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"11","key":"10.1016\/j.jsmc.2020.02.002_bib80","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/sleep\/33.11.1553","article-title":"Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia","volume":"33","author":"Krystal","year":"2010","journal-title":"Sleep"},{"key":"10.1016\/j.jsmc.2020.02.002_bib81","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.sleep.2017.03.007","article-title":"Treatment of insomnia with tricyclic antidepressants: a meta-analysis of polysomnographic randomized controlled trials","volume":"34","author":"Liu","year":"2017","journal-title":"Sleep Med"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.002_bib82","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/(SICI)1099-1077(199804)13:3<191::AID-HUP972>3.0.CO;2-X","article-title":"Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia","volume":"13","author":"Walsh","year":"1998","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"10.1016\/j.jsmc.2020.02.002_bib83","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2125.1983.tb04977.x","article-title":"Trazodone enhances sleep in subjective quality but not in objective duration","volume":"16","author":"Montgomery","year":"1983","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.002_bib84","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2869.2011.00928.x","article-title":"Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs","volume":"20","author":"Roth","year":"2011","journal-title":"J\u00a0Sleep Res"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.002_bib85","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/sj.npp.1300923","article-title":"Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine","volume":"31","author":"Schmid","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.jsmc.2020.02.002_bib86","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/sleep\/25.6.666","article-title":"The effects of mirtazapine on sleep: a placebo controlled, double-blind study\u00a0in young healthy volunteers","volume":"25","author":"Aslan","year":"2002","journal-title":"Sleep"},{"issue":"10","key":"10.1016\/j.jsmc.2020.02.002_bib87","first-page":"1433","article-title":"Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia","volume":"34","author":"Krystal","year":"2011","journal-title":"Sleep"},{"issue":"5","key":"10.1016\/j.jsmc.2020.02.002_bib88","doi-asserted-by":"crossref","first-page":"977","DOI":"10.5665\/sleep.3674","article-title":"Differential effect of an anticholinergic antidepressant on sleep-dependent memory consolidation","volume":"37","author":"Goerke","year":"2014","journal-title":"Sleep"},{"key":"10.1016\/j.jsmc.2020.02.002_bib89","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.smrv.2017.06.002","article-title":"The influence of antidepressants on restless legs syndrome and periodic limb movements: a systematic review","volume":"38","author":"Kolla","year":"2018","journal-title":"Sleep Med Rev"},{"issue":"8","key":"10.1016\/j.jsmc.2020.02.002_bib90","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/sleep\/27.8.1441","article-title":"Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine","volume":"27","author":"Walsh","year":"2004","journal-title":"Sleep"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.002_bib91","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00213-003-1759-5","article-title":"Sleep-promoting properties of quetiapine in healthy subjects","volume":"174","author":"Cohrs","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"10.1016\/j.jsmc.2020.02.002_bib92","first-page":"729","article-title":"Quetiapine for primary insomnia: a double blind, randomized controlled trial","volume":"93","author":"Tassniyom","year":"2010","journal-title":"J\u00a0Med Assoc Thai"},{"issue":"5","key":"10.1016\/j.jsmc.2020.02.002_bib93","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1345\/aph.1Q697","article-title":"Safety of low doses of quetiapine when used for insomnia","volume":"46","author":"Coe","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jsmc.2020.02.002_bib94","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.sleep.2016.04.003","article-title":"Atypical antipsychotics for insomnia: a systematic review","volume":"22","author":"Thompson","year":"2016","journal-title":"Sleep Med"},{"key":"10.1016\/j.jsmc.2020.02.002_bib95","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.smrv.2016.05.002","article-title":"The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia","volume":"33","author":"Monti","year":"2017","journal-title":"Sleep Med Rev"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.002_bib96","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.smrv.2012.09.005","article-title":"Insomnia with objective short sleep duration: the most biologically severe phenotype of the disorder","volume":"17","author":"Vgontzas","year":"2013","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.jsmc.2020.02.002_bib97","series-title":"Stahl\u2019s Essential Pharmacology: The prescriber\u2019s guide","first-page":"703","article-title":"Temazepam","author":"Stahl","year":"2017"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.002_bib98","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1365-2125.2003.01775.x","article-title":"Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam","volume":"55","author":"Yasui-Furukori","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jsmc.2020.02.002_bib99","unstructured":"Available at: https:\/\/www.drugs.com. Accessed February 19, 2018."}],"container-title":["Sleep Medicine Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556407X20300138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556407X20300138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:01:12Z","timestamp":1761562872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556407X20300138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1556407X20300138"],"URL":"https:\/\/doi.org\/10.1016\/j.jsmc.2020.02.002","relation":{},"ISSN":["1556-407X"],"issn-type":[{"value":"1556-407X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescription Drugs Used in Insomnia","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsmc.2020.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}